Meanwhile, the anti-TM4SF1 antibody decreased the level of phosphorylated PKCα, and also reduced DNM2 levels in cancer patients' platelets, but had little effect on total PKCα levels (Fig. 6E). The gene discussed is DNM2; the disease is cancer.